Physician profile
Malini Soogoor
NPI 1659328185
$1,850.16
in general payments reported to CMS, 2019-2025
11 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.86 · 2020: $317 · 2021: $271 · 2022: $240 · 2023: $426 · 2024: $315 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $462.57 | 2021-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $370.29 | 2020-2025 | Nuzyra |
| Cipla USA INC. | $296.19 | 2020-2022 | |
| Melinta Therapeutics, LLC | $216.40 | 2019-2024 | Rezzayo, Kimyrsa |
| Gilead Sciences, INC. | $180.84 | 2023-2025 | Vemlidy, Veklury |
| Merck Sharp & Dohme LLC | $129.12 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Abbvie INC. | $104.44 | 2021-2025 | |
| La Jolla Pharmaceutical Company | $36.92 | 2023 | Xerava, Xacduro |
| Allergan, INC. | $26.75 | 2019-2020 | |
| Insmed, INC. | $26.64 | 2025 | Arikayce |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malini Soogoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.